CDC launches campaign to educate public about prescription opioid risks

Sep 29, 2017 - 02:29 PM

The Centers for Disease Control and Prevention this week launched Rx Awareness, a communications campaign to educate the public about the risks associated with prescription opioids to prevent misuse and overdose. The campaign includes video, audio and online messages featuring real-life accounts of people recovering from opioid use disorder or who have lost loved ones to prescription opioid overdose. Campaign ads will run for 14 weeks in Ohio, Kentucky, Massachusetts, and New Mexico, with additional states planned. CDC also encourages organizations to promote the messages on their social media channels. The AHA and CDC last year released a one-page patient education resource as a tool for hospitals and medical staffs to use in their conversations with patients who may be prescribed opioids.

Related News Articles

Headline
Overdose deaths dropped an estimated 27% in 2024
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…
Headline
Study finds AI screening for OUD led to fewer hospital readmissions 
The National Institutes of Health April 3 released a study that found an artificial intelligence screening tool was as effective as health care providers in…
Headline
HHS extends public health emergency for opioid crisis
The Department of Health and Human Services March 18 announced that it renewed the public health emergency for the nation’s opioid crisis an additional 90 days…
Headline
OIG report finds just 40% of Medicare enrollees who started treatment for opioid use disorder continued
The Department of Health and Human Services Office of Inspector General Feb. 18 released a report that found about 40% of Medicare enrollees who began opioid…
Headline
DEA and HHS delay implementation of buprenorphine final rule
Today the Drug Enforcement Administration and Department of Health and Human Services announced that the effective date for the final rule regarding…
Headline
FDA approves first-in-class non-opioid painkiller 
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…